About

Christopher Van Gundy is a partner in the Business Trial Practice Group in the firm's San Francisco office.

Latest Post

On November 25, 2019, FDA issued Warning Letters to 15 companies illegally marketing cannabidiol (CBD) products. On the same day, U.S. Food & Drug Administration (FDA) published a revised consumer update, “What You Need to Know (And What We’re Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD,” describing the “very limited” scientific information available about CBD and its health effects. The points made in the Warning Letters and update are nothing new to those closely following the FDA working group on cannabis and CBD, but the actions signal the FDA’s continued enforcement against… Continue Reading FDA Issues Warning Letters to 15 Companies, Consumer Update on CBD Safety

About

Christopher Van Gundy is a partner in the Business Trial Practice Group in the firm's San Francisco office.